Grant: Project Grant

Prostate cancer (PCa) is the most common cancer type in males in Western countries. Following surgery or radiotherapy, standards of care for recurrent PCa are to block the androgen receptor (AR), either with androgen deprivation therapy or anti-androgen treatment. Despite positive response initially to these therapies, progression to lethal castration-resistant PCa is inevitable, highlighting the need to develop new approaches to treat this cancer. In the current project, we investigate the possibility to target cell metabolism as a new therapeutic approach.